# A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

> **NCT05440344** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 27 (actual)

## Conditions studied

- Hepatic Insufficiency
- Healthy

## Interventions

- **DRUG:** Imlunestrant

## Key facts

- **NCT ID:** NCT05440344
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-05
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05440344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05440344, "A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05440344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*